[{"id":"80a15019-c76b-402b-869e-abfd7ab973d5","acronym":"PRO1184-001","url":"https://clinicaltrials.gov/study/NCT05579366","created_at":"2022-10-13T16:56:38.872Z","updated_at":"2024-07-02T16:35:06.017Z","phase":"Phase 1/2","brief_title":"PRO1184 for Advanced Solid Tumors","source_id_and_acronym":"NCT05579366 - PRO1184-001","lead_sponsor":"ProfoundBio US Co.","biomarkers":" HER-2 • FOLR1","pipe":" | ","alterations":" HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • Rina-S (rinatabart sesutecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 374","initiation":"Initiation: 12/07/2022","start_date":" 12/07/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-05-03"}]